Brief: Adagene Announces Clinical Advancement For Adg116
29/03/2021 13:15
March 29 (Reuters) - Adagene Inc ADAG.O :
* ADAGENE ANNOUNCES CLINICAL ADVANCEMENT FOR ADG116
* ADAGENE INC - NEOBODY PRODUCT CANDIDATE ADG116 HAS BEEN
WELL
TOLERATED IN ONGOING PHASE 1 CLINICAL TRIAL
* ADAGENE INC - NO DRUG RELATED GRADE 3 AND GRADE 4
TOXICITIES
HAVE BEEN OBSERVED IN ONGOING PHASE 1 CLINICAL TRIAL
Source text for Eikon: ID:nGNX1GCfRT
Further company coverage: ADAG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate